IMMUNE DESIGN CORP.
IMDZ evidence brief
What we can confirm
- BioSniper Score:
- 7.9 / 10
- Lead Asset:
- ca21 (Preclinical)
What it means
What to watch
Prepared research question
What matters most for IMDZ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
ca21 (Preclinical)
Next Catalyst
—
Tracking 4 pipeline candidates for IMMUNE DESIGN CORP..
Run IMMUNE DESIGN CORP. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available IMMUNE DESIGN CORP. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is IMMUNE DESIGN CORP.'s lead drug candidate?
IMMUNE DESIGN CORP.'s most advanced tracked candidate is ca21 (Preclinical) for Oncology.
Who is the CEO of IMMUNE DESIGN CORP.?
Carlos V. Paya, M.D. is the chief executive officer of IMMUNE DESIGN CORP. (IMDZ).
What therapeutic areas does IMMUNE DESIGN CORP. focus on?
IMMUNE DESIGN CORP. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.